Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Resetting Old And Building New Product Planks In India

Executive Summary

GlaxoSmithKline is looking to rebuild in India its topical antibiotic brand Neosporin, which has returned to the market after an almost two-year absence following supply issues, while a new - seemingly India-specific - thrust in prescription probiotics and momentum in vaccines are also seen driving local growth this year.

You may also be interested in...



Portfolio Streamlining At GSK India But Long Term Commitment Intact

GlaxoSmithKline has initiated portfolio rationalization measures in India as the British multinational reshapes its emerging markets business model with an eye on driving sustained profitable growth. But the company has also underscored its long-term commitment to the country, where it expects to build on its “strong heritage” and expand patient access.

Interview: Revolution At GSK India

Brace for GSK India's new avatar. The British multinational is revamping its business model in India and donning a new approach to create, deliver and capture value via a "one team" effort as it strives to emerge as the fastest growing pharma multinational in the country by 2020.

Pre-work Rigor, 'Clean' Documentation Are Key As US FDA Unlocks Remote Inspection Tools

A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency  deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel